Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE